Inhibition of mouse SP2/0 myeloma cell growth by the B7-H4 protein vaccine

  • Mu, Nan (State Key Laboratory of Cancer Biology, Biotechnology Center, School of Pharmacy) ;
  • Liu, Nannan (Experiment Teaching Center of Basic Medicine, The Fourth Military Medical University) ;
  • Hao, Qiang (State Key Laboratory of Cancer Biology, Biotechnology Center, School of Pharmacy) ;
  • Xu, Yujin (State Key Laboratory of Cancer Biology, Biotechnology Center, School of Pharmacy) ;
  • Li, Jialin (State Key Laboratory of Cancer Biology, Biotechnology Center, School of Pharmacy) ;
  • Li, Weina (State Key Laboratory of Cancer Biology, Biotechnology Center, School of Pharmacy) ;
  • Wu, Shouzhen (State Key Laboratory of Cancer Biology, Biotechnology Center, School of Pharmacy) ;
  • Zhang, Cun (State Key Laboratory of Cancer Biology, Biotechnology Center, School of Pharmacy) ;
  • Su, Haichuan (Department of Oncology, Tangdu Hospital, Fourth Military Medical University)
  • Received : 2013.07.22
  • Accepted : 2013.11.13
  • Published : 2014.07.31


B7-H4 is a member of B7 family of co-inhibitory molecules and B7-H4 protein is found to be overexpressed in many human cancers and which is usually associated with poor survival. In this study, we developed a therapeutic vaccine made from a fusion protein composed of a tetanus toxoid (TT) T-helper cell epitope and human B7-H4IgV domain (TT-rhB7-H4IgV). We investigated the anti-tumor effect of the TT-rhB7-H4IgV vaccine in BALB/c mice and SP2/0 myeloma growth was significantly suppressed in mice. The TT-rhB7-H4IgV vaccine induced high-titer specific antibodies in mice. Further, the antibodies induced by TT-rhB7-H4IgV vaccine were capable of depleting SP2/0 cells through complement-dependent cytotoxicity (CDC) in vitro. On the other hand, the poor cellular immune response was irrelevant to the therapeutic efficacy. These results indicate that the recombinant TT-rhB7-H4IgV vaccine might be a useful candidate of immunotherapy for the treatment of some tumors associated with abnormal expression of B7-H4.


Supported by : National Natural Foundation of China


  1. Prasad, D. V., Richards, S., Mai, X. M. and Dong, C. (2003) B7S1, a novel B7 family member that negatively regulates T cell activation. Immunity 18, 863-873.
  2. Choi, I. H., Zhu, G., Sica, G. L., Strome, S. E., Cheville, J. C., Lau, J. S., Zhu, Y., Flies, D. B., Tamada, K. and Chen, L. (2003) Genomic organization and expression analysis of B7-H4, an immune inhibitory molecule of the B7 family. J. Immunol. 171, 4650-4654.
  3. Sica, G. L., Choi, I. H., Zhu, G., Tamada, K., Wang, S. D., Tamura, H., Chapoval, A. I., Flies, D. B., Bajorath, J. and Chen, L. (2003) B7-H4, a molecule of the B7 family, negatively regulates T cell immunity. Immunity 18, 849-861.
  4. Salceda, S., Tang, T., Kmet, M., Munteanu, A., Ghosh, M., Macina, R., Liu, W., Pilkington, G. and Papkoff, J. (2005) The immunomodulatory protein B7-H4 is overexpressed in breast and ovarian cancers and promotes epithelial cell transformation. Exp. Cell Res. 306, 128-141.
  5. Krambeck, A. E., Thompson, R. H., Dong, H., Lohse, C. M., Park, E. S., Kuntz, S. M., Leibovich, B. C., Blute, M. L., Cheville, J. C. and Kwon, E. D. (2006) B7-H4 expression in renal cell carcinoma and tumor vasculature: associations with cancer progression and survival. Proc. Natl. Acad. Sci. U.S.A. 103, 10391-10396.
  6. Fauci, J. M., Straughn, J. M., Jr., Ferrone, S. and Buchsbaum, D. J. (2012) A review of B7-H3 and B7-H4 immune molecules and their role in ovarian cancer. Gynecol. Oncol. 127, 420-425.
  7. Simon, I., Katsaros, D., Rigault de la Longrais, I., Massobrio, M., Scorilas, A., Kim, N. W., Sarno, M. J., Wolfert, R. L. and Diamandis, E. P. (2007) B7-H4 is over-expressed in early-stage ovarian cancer and is independent of CA125 expression. Gynecol. Oncol. 106, 334-341.
  8. Quandt, D., Fiedler, E., Boettcher, D., Marsch, W. and Seliger, B. (2011) B7-h4 expression in human melanoma: its association with patients' survival and antitumor immune response. Clin. Cancer Res. 17, 3100-3111.
  9. Chen, L. J., Sun, J., Wu, H. Y., Zhou, S. M., Tan, Y., Tan, M., Shan, B. E., Lu, B. F. and Zhang, X. G. (2011) B7-H4 expression associates with cancer progression and predicts patient's survival in human esophageal squamous cell carcinoma. Cancer Immunol. Immunother. 60, 1047-1055.
  10. Sun, S. Q., Jiang, C. G., Lin, Y., Jin, Y. L. and Huang, P. L. (2012) Enhanced T cell immunity by B7-H4 downregulation in nonsmall-cell lung cancer cell lines. J. Int. Med. Res. 40, 497-506.
  11. Kryczek, I., Zou, L., Rodriguez, P., Zhu, G., Wei, S., Mottram, P., Brumlik, M., Cheng, P., Curiel, T., Myers, L., Lackner, A., Alvarez, X., Ochoa, A., Chen, L. and Zou, W. (2006) B7-H4 expression identifies a novel suppressive macrophage population in human ovarian carcinoma. J. Exp. Med. 203, 871-881.
  12. Dalum, I., Butler, D. M., Jensen, M. R., Hindersson, P., Steinaa, L., Waterston, A. M., Grell, S. N., Feldmann, M., Elsner, H. I. and Mouritsen, S. (1999) Therapeutic antibodies elicited by immunization against TNF-alpha. Nat. Biotechnol. 17, 666-669.
  13. Dalum, I., Jensen, M. R., Gregorius, K., Thomasen, C. M., Elsner, H. I. and Mouritsen, S. (1997) Induction of cross-reactive antibodies against a self protein by immunization with a modified self protein containing a foreign T helper epitope. Mol. Immunol. 34, 1113-1120.
  14. Valmori, D., Pessi, A., Bianchi, E. and Corradin, G. (1992) Use of human universally antigenic tetanus toxin T cell epitopes as carriers for human vaccination. J. Immunol. 149, 717-721.
  15. Yu, Z., Healy, F., Valmori, D., Escobar, P., Corradin, G. and Mach, J. P. (1994) Peptide-antibody conjugates for tumour therapy: a MHC-class-II-restricted tetanus toxin peptide coupled to an anti-Ig light chain antibody can induce cytotoxic lysis of a human B-cell lymphoma by specific CD4 T cells. Int. J. Cancer 56, 244-248.
  16. Zhang, C., Wang, W., Qin, X., Xu, Y., Huang, T., Hao, Q., Li, W., Wu, S. and Zhang, Y. (2013) B7-H1 protein vaccine induces protective and therapeutic antitumor responses in SP2/0 myeloma-bearing mice. Oncol. Rep. 30, 2442-2448.
  17. Suh, W. K., Wang, S., Duncan, G. S., Miyazaki, Y., Cates, E., Walker, T., Gajewska, B. U., Deenick, E., Dawicki, W., Okada, H., Wakeham, A., Itie, A., Watts, T. H., Ohashi, P. S., Jordana, M., Yoshida, H. and Mak, T. W. (2006) Generation and characterization of B7-H4/B7S1/B7x-deficient mice. Mol. Cell Biol. 26, 6403-6411.
  18. Hansen, J. D., Du Pasquier, L., Lefranc, M. P., Lopez, V., Benmansour, A. and Boudinot, P. (2009) The B7 family of immunoregulatory receptors: a comparative and evolutionary perspective. Mol. Immunol. 46, 457-472.
  19. Zhang, C., Wu, S., Xue, X., Li, M., Qin, X., Li, W., Han, W. and Zhang, Y. (2008) Anti-tumor immunotherapy by blockade of the PD-1/PD-L1 pathway with recombinant human PD-1-IgV. Cytotherapy 10, 711-719.
  20. Kryczek, I., Wei, S., Zhu, G., Myers, L., Mottram, P., Cheng, P., Chen, L., Coukos, G. and Zou, W. (2007) Relationship between B7-H4, regulatory T cells, and patient outcome in human ovarian carcinoma. Cancer Res. 67, 8900-8905.
  21. Lin, C. C., Chou, C. W., Shiau, A. L., Tu, C. F., Ko, T. M., Chen, Y. L., Yang, B. C., Tao, M. H. and Lai, M. D. (2004) Therapeutic HER2/Neu DNA vaccine inhibits mouse tumor naturally overexpressing endogenous neu. Mol. Ther. 10, 290-301.
  22. Renard, V., Sonderbye, L., Ebbehoj, K., Rasmussen, P. B., Gregorius, K., Gottschalk, T., Mouritsen, S., Gautam, A. and Leach, D. R. (2003) HER-2 DNA and protein vaccines containing potent Th cell epitopes induce distinct protective and therapeutic antitumor responses in HER-2 transgenic mice. J. Immunol. 171, 1588-1595.

Cited by

  1. Immunosuppressive Effect of B7-H4 Pathway in a Murine Systemic Lupus Erythematosus Model vol.8, pp.1664-3224, 2017,
  2. Construction, expression and functional analysis of anti-B7-H4-scFv-CH3 recombinant antibody vol.43, pp.4, 2018,